ACADIA Pharmaceuticals Reports First Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Acadia Pharma (ACAD) Misses Q1 EPS by 13c
May 7, 2015 4:26 PM EDTAcadia Pharma (NASDAQ: ACAD) reported Q1 EPS of ($0.40), $0.13 worse than the analyst estimate of ($0.27). Revenue for the quarter came in at $4 thousand versus the consensus estimate of $80 thousand.
For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.
... More